Clinical Trial Update: A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase II trial comparing quality of life, tolerability and toxicity of PEG Intron versus INTRON A in patients with Multiple Myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Intron A (interferon alfa-2b)
• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED